Innovative Multidisciplinary Strategies for Combating Severe Dengue
Advancing Pandemic Preparedness: Innovative Multidisciplinary Strategies for COMBATing Severe Dengue
Karolinska Institutet
1,400 participants
Jan 3, 2025
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions. The main question it aims to answer is: Can multi-omics approaches predict disease severity and identify key factors contributing to severe dengue infections? Participants will include individuals with dengue infection, and the study will analyze their blood samples using multi-omics techniques to uncover host immune responses, disease pathogenesis, and cellular pathway interactions. The study will also assess the role of primary and secondary infections, virus serotypes, and immunological factors in disease progression. Findings aim to support disease management, improve severity prediction, and identify potential therapeutic targets to prevent severe outcomes.
Eligibility
Inclusion Criteria19
- Group 1: Dengue without warning signs Patients presenting with the following symptoms confirmed positive for dengue infection by lab diagnosis by anti-dengue IgM or NS1 ELISA will be recruited for the study under this cohort.
- Symptoms will be fever along with at least two of the following -
- Myalgia, arthralgia
- Nausea and/or vomiting
- Rashes
- Leukopenia Group 2: DENV with warning signs This cohort will include patients with the above symptoms and any of the following clinical signs.
- Abdominal pain with tenderness
- Persistent vomiting
- Fluid accumulation
- Mucosal bleeding
- Restlessness, lethargy
- Liver enlargement >2cm
- Laboratory findings: An increase in hematocrit levels and a rapid decrease in platelet count Group 3: Severe dengue
- Severe plasma leakage leads to hypovolemic shock (dengue shock syndrome) and fluid accumulation with respiratory distress.
- Severe bleeding, such as epistaxis, internal bleeding, etc., is evaluated by a clinician.
- Severe organ involvement with any of the following symptoms
- Liver AST or ALT ≥ 1000
- CNS: impaired consciousness
- Heart and other organs failure
Exclusion Criteria1
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
No intervention apart from the dengue infection
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06751836